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Aims Circulating angiogenic cells (CACs) promote revascularization of ischaemic tissues although their underlying mecha-
nism of action and the consequences of delivering varying number of these cells for therapy remain unknown. This
study investigates molecular mechanisms underpinning CAC modulation of blood vessel formation.
....................................................................................................................................................................................................
Methods
and results
CACs at low (2  105 cells/mL) and mid (2  106 cells/mL) cellular densities significantly enhanced endothelial cell
tube formation in vitro, while high density (HD) CACs (2  107 cells/mL) significantly inhibited this angiogenic proc-
ess. In vivo, Matrigel-based angiogenesis assays confirmed mid-density CACs as pro-angiogenic and HD CACs as
anti-angiogenic. Secretome characterization of CAC-EC conditioned media identified pentraxin 3 (PTX3) as only
present in the HD CAC-EC co-culture. Recombinant PTX3 inhibited endothelial tube formation in vitro and in vivo.
Importantly, our data revealed that the anti-angiogenic effect observed in HD CAC-EC co-cultures was significantly
abrogated when PTX3 bioactivity was blocked using neutralizing antibodies or PTX3 siRNA in endothelial cells. We
show evidence for an endothelial source of PTX3, triggered by exposure to HD CACs. In addition, we confirmed
that PTX3 inhibits fibroblast growth factor (FGF) 2-mediated angiogenesis, and that the PTX3 N-terminus, contain-
ing the FGF-binding site, is responsible for such anti-angiogenic effects.
....................................................................................................................................................................................................
Conclusion Endothelium, when exposed to HD CACs, releases PTX3 which markedly impairs the vascular regenerative
response in an autocrine manner. Therefore, CAC density and accompanying release of angiocrine PTX3 are critical
considerations when using these cells as a cell therapy for ischaemic disease.
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1. Introduction
Cell therapy to promote vascular regeneration in ischaemic tissues is an
emergent therapeutic strategy and there are already clinical trials for acute
myocardial infarction1 and critical limb ischaemia.2 These clinical trials have
shown such cytotherapies to be safe, tolerable, and feasible; however, clini-
cal efficacy outcomes have been inconsistent. Therefore the development
of an efficacious cytotherapy requires a better understanding of the biol-
ogy of the cells used, the most effective dosage, and precise mechanisms
of action. We have previously characterized two distinct types of human
endothelial progenitor cells (EPCs): endothelial colony forming cells
(ECFCs) and circulating angiogenic cells (CACs).3 CACs, also called early
EPCs or myeloid angiogenic cells, are isolated from human peripheral
blood and have been shown to assist vascular repair through paracrine
mechanisms, partly explained by IL8 secretion resulting in VEGFR2 trans-
activation.4 While CACs represent candidate cells for cytotherapy, their
intrinsic haematopoietic nature requires further understanding of the
molecular mechanisms that dictate endothelial cell responses.
Cell populations with similar phenotypes to CACs, are currently being
clinically trialled as a therapy for acute myocardial infarction5 and
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pulmonary arterial hypertension.6 Other similar cell therapy trials such
as TOPCARE-AMI,7 BOOST,8 and Repair-AMI9 have used autologous
bone marrow (BM)-derived cells. These have shown some beneficial effects
in improving left ventricular ejection fraction although their effectiveness
has been challenged by the acute myocardial infarction bone marrow-
derived stem cell (BMSC)10 and the autologous stem cell transplantation in
acute myocardial infarction (ASTAMI)11 trials which showed no significant
improvement in ejection fraction at 4 and 6 month follow-up. It is important
to highlight that these studies delivered very different cell densities in their
clinical protocols. Indeed, the minimum therapeutic dose is a critical factor
that must be addressed in appropriately designed dose-escalating clinical tri-
als. In addition, the ceiling effect, well demonstrated in the field of mesen-
chymal stromal cells, whereby increasing cell number reaches a threshold
where higher cell numbers fail to provide additional therapeutic effect,12
also needs to be considered. As CAC-based cytotherapy translates into the
clinical setting, safety dose-escalating studies such as the PHACeT6 trial are
warranted, and it is essential to understand the impact of cellular density on
CACs vasoreparative function. This investigation uses various experimental
models to determine how CAC cell dose modulates endothelial function.
Pentraxin 3 (PTX3) is a soluble pattern recognition protein, produced
and released by endothelial and myeloid cells, in response to inflamma-
tory stimuli such as IL-1b, TNF-a, and lipopolysaccharide (LPS).13
Besides the classical role for PTX3 in the innate immune response, this
protein has also been shown to inhibit blood vessel formation.14 Our
data identified PTX3 as a critical modulator of angiogenesis in high den-
sity (HD) CAC-endothelial cell co-cultures. Here, we present evidence
to demonstrate that the cross-talk between abundant CACs and endo-
thelial cells induces PTX3 expression and release. This endothelium-
derived PTX3 has an autocrine anti-angiogenic effect, mediated by fibro-
blast growth factor 2 (FGF2) binding and neutralization that explains
why high-CAC numbers, do not facilitate but in fact, impair the vasore-
parative process.
2. Methods
Detailed methods are available in online supplement.
2.1 Cell isolation and culture
Human peripheral blood was obtained under full ethical approval
granted by Queen’s University Research Ethical Committee Ref 14.44v2.
Appropriate consent was obtained from healthy volunteers aged 18–50
years, in accordance with the declaration of Helsinki. The mononuclear
cell (MNC) fraction was isolated and cells seeded at a density of 2 106
cells/mL in fibronectin-coated flasks and cultured in EGM2-MV medium
(Lonza) supplemented with 10% FBS.
2.2 RNA extraction and RT-qPCR
Total RNA was extracted and cDNA was synthesized using High-
Capacity RNA-to-cDNA Kit (Life Technologies). Quantitative real-time
PCR was performed for 50 cycles in a LightCycler 480 (Roche). Primer
sequences are shown in Supplementary material online, Table S1.
2.3 siRNA knockdown
Cells were transfected at 80% confluence with 10 nm siRNA using
Lipofectamine 2000 for 16 h, passaged and used for experimental analy-
sis within 24–48 h. PTX3 siRNA (s11585) and control siRNA were pur-
chased from Life Technologies.
2.4 Western blotting
Protein was extracted by lysing cells in radioimmunoprecipitation assay
(RIPA) buffer containing protease and phosphatase inhibitors (Thermo
Scientific). 30 mg of protein was loaded onto sodium dodecyl sulfate
(SDS) gels. After electrophoresis, proteins were transferred onto polyvi-
nylidene difluoride (PVDF) membranes, which were incubated overnight
at 4 C with rabbit PTX3 antibody (Abcam). Next, membranes were
washed and incubated with secondary antibodies (Advansta). Blots were
developed using chemiluminescent horseradish peroxidase (HRP) sub-
strate (Millipore).
2.5 Immunocytochemistry
CACs were fixed in 4% paraformaldehyde (PFA), blocked and incubated
overnight at 4C with primary antibodies. After washing in phosphate
buffered saline (PBS), cells were incubated in appropriate secondary anti-
bodies for 1 h at room temperature and observed under a confocal fluo-
rescence microscope (Nikon). Primary antibodies used were against
Vimentin (Dako), CD31 (Abcam), VEGFR2, and CD14 (Santa Cruz).
Respective anti-mouse/anti-rat and anti-rabbit Alexa Flour 488 and 568
IgGs (Molecular Probes, Invitrogen) were used as secondary antibodies.
2.6 Flow cytometry
Live cells were incubated with antibodies against CD3, CD14, CD16,
CD20, CD45, CD16, CD163, CD235 (eBioscience), CD66b (Abcam),
and CD206 (BD Biosciences). After a wash in PBS, cells were resus-
pended in 1 mL of staining buffer for analysis using an Attune acoustic
cytometer (Life Technologies). At least 20 000 events were acquired for
each sample and FlowJo software was used for data analysis.
2.7 In vitro tubulogenesis assay
CACs and microvascular endothelial cells (MECs) were labelled with
PKH fluorescent cell linker kit (Sigma) prior to experiments. CACs were
mixed at a low density (LD) 5  1031  104, a medium density (MD)
5 1041 105 and a HD 5 1051 106 with 1 105 MECs. Cell
suspensions in 25 mL were mixed with 25 mL of growth factor-reduced
Matrigel (Corning) and the final 50 lL aliquots were spotted onto a
24-well plate. After polymerization, spots were covered with
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% porcine
serum. After 24–72 h, wells were assessed for the presence of tubules. In
a different set of experiments, conditioned medium (CM) taken from
CAC-MEC co-cultures was used in this tubulogenesis model with MECs.
2.8 In vivo Matrigel subcutaneous implant
assay
All animal experiments were performed in conformity to UK Home Office
Regulations (PPL2729) and with authorization from Queen’s University
Belfast Animal Welfare and Ethical Review Body (AWERB). Eight week-old
male Athymic nude mice (Harlan Laboratories) were used. CACs were
mixed at a LD 2  104, a MD 2  105, and a HD 2  106 with 2  105
MECs, diluted in 10 mL of phenol red-free DMEM and resuspended in 90
mL of growth factor-reduced Matrigel (Corning) and injected subcutane-
ously. After 8 days, mice were sacrificed using intraperitoneal (IP) adminis-
tration of sodium pentobarbital at 200 mg/kg, and implants were removed
and fixed in 4% formaldehyde overnight. Fixed Matrigel implants were then
embedded in paraffin and 10 mm sections were prepared for staining.
2 C.L. O’Neill et al.
by guest on O
ctober 28, 2016
D
ow
nloaded from
 
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..2.9 Oxygen induced retinopathy (OIR)
model
All animal experiments were performed in conformity to UK Home
Office Regulations (PPL2729) and with authorization from Queen’s
University Belfast AWERB. P7 newborn mice and their nursing dams
were exposed to 75% oxygen (Pro-Ox 110 Chamber Controller,
Biospherix) for 5 days. At P12, they were transferred back to room air.
At P13, mice received a 1 lL intravitreal injection of 100 ng/mL recombi-
nant human PTX3 in the left eye. Phenol red-free DMEM without
growth factors and serum (GIBCOVR ) was used as vehicle and injected in
the contralateral right eye of each pup as a control. All pups were
euthanized at P16 and eyes fixed in 4% PFA with sodium pentobarbital at
200 mg/Kg. Flat-mounted retinas were stained with isolectin B4 (Sigma)
and streptavidin-AlexaFlour488 (Invitrogen).
2.10 Human angiogenesis antibody array
Conditioned media was analysed using the proteome profiler human
angiogenesis array (R&D Systems) in accordance with manufacturer
guidelines. Membranes were incubated with streptavidin–horseradish
peroxidase secondary antibody and spots were detected using a UVP
bioimaging system. Densitometry was performed using Image J software.
2.11 PTX3 ELISA
The human PTX3 ELISA kit (MyBiosource) was used according to the
manufacturer instructions.
2.12 Cell viability assay
Cell viability was assessed using the LIVE/DEAD viability/cytotoxicity kit
(Invitrogen). As a positive control, to induce cell death we treated some
co-cultures with 70% ethanol prior to Calcein/EthD-1 staining.
2.13 Clonogenic assay
ECFCs were seeded onto 6 well plates at a density of 100 cells/mL
and wells monitored for the formation of colonies. After 10 days,
cells were fixed with glutaraldehyde 6.0% (vol/vol), stained with
crystal violet 0.5% (wt/vol) in distilled water for 30 min at room tem-
perature, and washed by immersion in a bath of water. The percent-
age of area occupied by crystal violet was quantified using Image J
software.
2.14 In vitro migration assay
Gelatin-coated 24 well plates were labelled with traced lines so as the
same regions were photographed at different time points. MECs were
seeded, and when confluent, the cell monolayer was scraped in a straight
line to create a ‘scratch’ with a p200 pipette tip. CACs at low, mid, and
HDs were layered on top of MEC monolayers. Images were taken
immediately after the scratch and after 12 h using a phase-contrast
microscope. Cell migration was quantified by comparing denuded area
at 0 and 12 h.
2.15 Statistical analysis
Statistical significance for comparison between two groups was eval-
uated using Prism software and unpaired two tailed t-test analysis. For
multiple comparisons, we used one way analysis of variance (ANOVA).
For the Oxygen induced retinopathy (OIR) study, data were evaluated
using Prism software and paired two tailed t-test analysis. Data visualiza-
tion was performed using the R package ggplot2 and represented as
individual data points together with means and standard error of the
mean (SEM).
3. Results
3.1 Cultured CACs are different from
density gradient-enriched MNCs
After 7 days in culture, CACs exhibited spindle-shaped and spherical
morphologies for the main and minor populations, respectively. CACs
used in this study were characterized by the positive expression of
vimentin, CD31, VEGFR2, and CD14 (Figure 1A). Immunophenotyping
was performed to further distinguish various blood cell populations
within CACs (green histograms) from MNCs (orange histograms) and
whole blood cells (red histograms). While whole blood was mainly com-
posed of erythrocytes (97%), MNCs obtained by density gradient frac-
tionation displayed minor erythrocyte contamination (3%), and CACs
were completely devoid of erythrocytes (0%). CD45 was highly
expressed at a similar level (97%) by both MNCs and CACs, while the
myeloid marker CD14 was enriched in CACs (82%) when compared to
MNCs (20%) (Figure 1B). This characterization also indicated that the T
cell marker CD3 was highly expressed on MNCs (61%), while minor
expression was found on CACs (3%). Similarly, the B lymphocyte
marker CD20 was completely absent in CACs (0%) while present in 2%
of MNCs. CAC cultures were also devoid of granulocytes (0%) which
represented 19% of MNCs as demonstrated by quantification of CD66b
positive cells. CACs display some characteristics shared with M2 macro-
phages such as high expression of CD163 (71%) and CD206 (56%).
These M2 markers were present on MNCs at lower levels (21 and 1%
respectively) (Figure 1C). These findings indicate that CACs are a
highly enriched population of myeloid cells, devoid of erythrocytes, B
lymphocytes, and granulocytes, with an immunophenotype akin to M2
macrophages.
3.2 Cellular density determines CACs
vasoreparative potential
To address whether the cellular density of CACs is an important factor
in determining their therapeutic potential, we used two well-established
angiogenesis assays, an in vitro Matrigel-based 3D tube formation assay
and an in vivo Matrigel subcutaneous implant assay. Taking into account
the cell dosage utilized by previous human clinical trials which have deliv-
ered cells directly into myocardium and vitreous, we selected a range of
CAC cell densities that are clinically-relevant. MECs were labelled in
green and CACs in red prior to co-culture. MECs formed a network of
tube-like structures within 72 h (Figure 2A). While CACs did not incor-
porate into these tubes and remained adjacent to the MEC vascular net-
work, addition of LD-CACs increased MEC tube formation when
compared to MECs alone/controls (Figure 2A and B). A 10-fold increase
in the cellular density of CACs to a mid-density (MD) led to further sig-
nificant enhancement of MEC tubulogenesis when compared to controls
(P< 0.01) (Figure 2A and B). Surprisingly, the addition of an even HD of
CACs (a 100-fold increase) to the co-culture system dramatically
reduced MEC tube formation when compared to controls (P< 0.01)
(Figure 2A and B). These results were confirmed in five different clones of
CACs (see Supplementary material online, Figure S1). Although the
extent of angiogenesis inhibition varied from clone to clone, HD-CACs
consistently diminished CACs pro-angiogenic effect. CM from co-
Pentraxin 3 and circulating angiogenic cells 3
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..culture experiments demonstrated similar outcomes, with CM from
HD-CACs significantly inhibiting MEC tube formation capacity
(Figure 2C). This indicated the presence of a soluble factor in the CM
from HD-CACsþMECs co-cultures which was responsible for the
observed suppressive effect on endothelial tube formation. A live/dead
cytotoxicity assay demonstrated no significant cell death (red nuclei)
among the co-cultures with different CAC cellular densities (Figure 2D).
All these in vitro results highlighted that cellular density of CACs is a crit-
ical factor in determining their angiogenic potential and revealed that a
high cellular density of CACs significantly inhibited endothelial cell tube
forming capacity. Similar results were seen in a MEC scratch wound
assay, which revealed a significant increase in MEC migration with the
addition of LD-CACs (P< 0.01), while HD-CACs resulted in a significant
reduction in MEC migration (P< 0.001) (see Supplementary material
online, Figure S2).
A Matrigel subcutaneous implant model was used as an in vivo
model to test the relevance of CAC cell density on angiogenesis.
Following the same protocols and conditions as for the previous
in vitro co-culture studies, MECs were mixed with different densities
of CACs in Matrigel and implanted subcutaneously into the dorsal
flank region of nude mice. After 8 days, Matrigel implants were
sampled and assessed for the degree of vascularity by CD31 immuno-
fluorescent staining. MD-CACsþMECs showed the highest vascular-
ity, when compared to other experimental groups (Figure 2E). On the
Figure 1 CACs isolated from human blood are enriched for myeloid cells. (A) Phase contrast image of CACs at Day 7 of culture. Scale bar 100lm.
Representative immunocytochemistry images for Vimentin, CD31, VEGFR2, and CD14 in green. Nuclei stained with DAPI in blue. Magnification 10 is
shown in upper panel and 40 in lower panel. (B) Flow cytometry immunophenotyping of whole blood, MNCs, and CACs. Red histograms show whole
blood cells, orange histograms MNCs and green histograms CACs. Respective isotype controls shown as grey histograms. (C) Flow cytometry quantification
of cell surface marker expression for T & B lymphocytes, granulocytes, and macrophages on MNCs and CACs. Orange histograms represent MNCs and
green histograms CACs. Respective isotype controls shown as grey histograms.
4 C.L. O’Neill et al.
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contrary, Matrigel implants containing HD-CACsþMECs showed sig-
nificantly decreased CD31þ staining when compared to the MD
group (P< 0.05) (Figure 2E). These in vivo data support in vitro findings
in demonstrating the loss of pro-angiogenic potential of CACs at high
cellular densities.
3.3 The secretome profile of CACþMECs
is altered by high-cellular density
Since HD-CACs-induced anti-angiogenic effects on MECs through
release of a soluble factor, we examined the secretome profiles of
Figure 2 The angiogenic potential of CACs is affected by their cellular density. (A) Representative images of green-labelled MECs and red-labelled CACs
co-culture after 72 h in the 3D Matrigel tube formation assay. Scale bar 250lm. (B) Quantification and statistical analysis of tube areas for experimental
groups depicted in A (n¼ 3–4, one way-ANOVA, **P< 0.01 vs. control, ###P< 0.001 vs. MD-CACs). (C) Evaluation of the effect for the CACs CM at differ-
ent densities on MEC tube forming capacity (n¼ 3, one-way ANOVA, *P< 0.05 vs. control, ##P< 0.01 vs. LD-CACs). (D) Representative images for cell
death assessment using the LIVE/DEAD kit. Dead cells shown in red by EthD-1 and live cells in green by calcein. Scale bar 250lm. Quantification of number
of dead cells per field of vision (FOV), (n¼ 8; unpaired t-test; ns , not significant). (E) Representative images of paraffin sections from the in vivoMatrigel angio-
genesis model in nude mice stained for the endothelial marker CD31 in red. Nuclei are stained in blue with DAPI. Matrigel implants are surrounded by yel-
low dotted line. Scale bar 250lm. Quantification and statistical analysis of CD31 positive areas within Matrigel implants (data visualized as boxplots,
n¼ 11–21, one-way ANOVA, ***P< 0.001 vs. control, *P< 0.05 vs. control; ns, not significant vs. control; #P< 0.05 vs. MD-CACs).
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CACsþMECs co-cultures by characterizing conditioned media from
previous in vitro co-culture experiments and profiling 55 secreted
angiogenesis-related proteins. Endothelin 1 was identified in the CM
from MECs alone (Figure 3A). In the LD-CACsþMECs co-culture, four
different proteins were secreted including IL8, TIMP-1, Endothelin 1, and
MMP-9. In the MD-CACsþMECs co-culture media, eight different pro-
teins were found, including MCP-1 and PAI-1. Overall, as expected, there
was an increase in the amount of protein with increasing cellular density
of CACs. However, in the HD-CACsþMECs co-culture, despite the
higher number of CACs, there was a significant decrease in IL8. In addi-
tion, two proteins were identified exclusively in the HD-CACþMEC
co-culture media: angiogenin and PTX3 (Figure 3A). Therefore subse-
quent experiments focused on these two proteins to identify the angio-
genesis inhibitor. Recombinant human angiogenin did not show any
inhibition of angiogenesis on MEC cultures; on the contrary, angiogenin
significantly enhanced MEC tubulogenesis (see Supplementary material
online, Figure S3). Similar experiments were performed with recombi-
nant human PTX3, which significantly reduced MEC tubulogenic capacity
(P< 0.001) (Figure 3B). Consequently, we decided to focus on PTX3 as
the soluble factor that modulates the anti-angiogenic effects seen in HD-
CACþMEC co-cultures.
3.4 PTX3 blocks angiogenesis in vitro and
in vivo
We next evaluated whether PTX3 was responsible for the anti-
angiogenic effects observed in HD-CAC cultures. MECs exposed to
PTX3 showed a significant reduction in tube formation when compared
to non-treated cells (P< 0.001) (Figure 3B). This effect of PTX3 was not
restricted to MECs, as human ECFCs and human aortic endothelial cells
also demonstrated a significant reduction in tubulogenesis induced by
PTX3 (P< 0.001) (Figure 3B and Supplementary material online, Figure
S4). In addition, ECFCs exhibited a significant reduction in cell migration
(P< 0.01) when treated with PTX3 (500 ng/mL) in the scratch wound
assay (see Supplementary material online, Figure S5).
To further test the effect of PTX3 in an in vivo disease-relevant setting,
we used the OIR model. OIR produces defined retinal ischaemia and has
been widely used to examine vascular repair. Recombinant PTX3 was
delivered intravitreally at post-natal day 13 (P13), the time point in which
the retina experiences primary hypoxic insult. After 72 h (P16), the reti-
nas were harvested and stained with isolectin B4 (green) to visualize the
retinal vasculature. It was observed that intravitreal injection of PTX3 did
not induce intra-retinal angiogenesis but significantly halted retinal blood
vessel formation as demonstrated by the significant increase in avascular
areas (P< 0.05) when compared to the retina in vehicle-injected con-
tralateral eyes (Figure 3C). Taken together, these findings indicate that
PTX3 suppresses endothelial function in vitro and in vivo and, importantly,
in a disease-relevant model of retinal ischaemia.
3.5 PTX3 mediates HD-CACs driven
anti-angiogenic effects on endothelial cells
To further test PTX3 role inhibiting angiogenesis in HD-CACþMEC
co-cultures, an antibody against PTX3 was used. Since PTX3 is com-
prised of a C-terminal domain shared with C-reactive protein and a
unique N-terminal domain, two specific monoclonal antibodies, 16B5
and MNB4, were used to target the PTX3 C-terminus and N-terminus
domains respectively. MECs were labelled with green PKH and CACs
with red PKH before co-culturing in the 3D in vitro Matrigel model. In
agreement with the previous results, while LD-CACs increased MEC
tube formation from 100% in MEC controls to 182% (Figure 4A and E),
co-culture with HD-CACs led to a significant reduction in MEC tubule
area (P< 0.001) to 51% of MEC controls (Figure 4B and E). Interestingly,
this effect was significantly abrogated (P< 0.001) by blocking the N-ter-
minus of PTX3 using a MNB4 antibody (Figure 4D) and MECs tube area
increased to 111% of MEC controls (Figure 4E). However, when we used
a 16B5 antibody that targets the C-terminus of PTX3, there was no sig-
nificant change on HD-CACs anti-angiogenic effects (Figure 4C and E),
and MECs tube area remained at a similar level as HD-CACþMECs
(52%). A rat IgG2a isotype control was used to account for any off-
target effects and this had no significant effect on HD-CACsþMEC co-
Figure 3 PTX3 is identified exclusively in the HD-CACsþMECs co-
culture and has anti-angiogenic function. (A) Proteome profiler for CM
characterization. Positive control protein spots are shown in top left,
top right, and bottom left corners. Negative control spots are on the
bottom right corner (n¼ 2). (B) Representative fluorescent micro-
scope images for the in vitro Matrigel-based 3D tube formation assay
with bovine MECs or human ECFCs labelled in green with Calcein, with
and without exposure to 500 ng/mL PTX3. Scale bar 250lm. Statistical
comparison of tube areas between groups (n¼ 6–9, unpaired t-test,
***P< 0.001 vs. control). (C) Representative flat-mounted retinas of
C57BL/6 mice that received an intravitreal injection of 1lL PTX3 at
100 ng/mL or 1 mL of vehicle. Lectin staining in green identifies retinal
vasculature. Avascular regions are surrounded by a yellow line. Scale
bar 1 mm. Quantification of avascular areas (n¼ 6, paired t-test,
*P< 0.05 comparing vehicle-treated and PTX3-treated eyes).
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cultures (see Supplementary material online, Figure S6). These data
reveal that specifically the N-terminus of PTX3, mediates
HD-CACsþMECs impairment of endothelial tube forming capacity.
3.6 Endothelium-derived PTX3 is sufficient
and necessary for HD-CACs induced
inhibition of MEC tube formation
As PTX3 was identified only in our HD co-culture system which con-
tained both HD-CACs and MECs, we investigated which of these two
cell types was the main source of PTX3. Analysis of conditioned media
collected from CACs and MECs by ELISA, confirmed that both these
cells release PTX3 under basal conditions although MECs released
significantly greater levels of PTX3 than CACs (see Supplementary
material online, Figure S7). Real-time quantitative PCR (RT-qPCR) of
RNA harvested from human CAC and bovine MEC co-cultures using
human or bovine specific primers for PTX3 revealed high expression
of PTX3 in the HD-CACsþMECs group with bovine-specific primers
and not with human-specific primers (Figure 5A). These data visualized
in a heatmap suggested that PTX3 was primarily being released by
MECs and not CACs (Figure 5A). Western blot analysis in human cells
also confirmed that human ECFCs express higher levels of PTX3 than
human CACs (Figure 5B). This was evident in four different biological
replicates. To further corroborate the finding that endothelial cells
were the primary source of PTX3 in our HD-CACþMECs co-
culture and to explore the functional significance of endothelial-
derived PTX3 in our system, PTX3 expression was knocked-down in
ECFCs using siRNA technology. ECFCs transfected with PTX3 siRNA
showed a significant decrease in PTX3 mRNA expression when com-
pared to scrambled siRNA-transfected ECFCs (Figure 5C).
Additionally, PTX3 knockdown in ECFCs was also confirmed at the
protein level by western blot (Figure 5D). These PTX3 siRNA-
transfected ECFCs and the corresponding scrambled siRNA-
transfected controls where co-cultured with HD-CACs (Figure 5E). In
agreement with the earlier results, HD-CACs led to a significant
reduction in endothelial tubule area in scrambled siRNA-transfected
control ECFCs (P< 0.001), however this inhibition of endothelial
tube forming capacity was significantly abrogated when PTX3 was
knocked-down in endothelial cells (P< 0.001) (Figure 5F). These
results confirmed that endothelial cells, in the presence of HD-CACs,
are the primary source of PTX3 which inhibits vascular tubule
formation.
3.7 The FGF pathway is targeted by
endothelium-derived PTX3
It has previously been reported that the N-terminus of PTX3 binds to
FGF2 and inhibits its pro-angiogenic activity.15 To investigate if this mech-
anism was responsible for the observed PTX3 effects, we performed
clonogenic assays using ECFCs in a modified cell culture media with low
serum and containing FGF2 as the only added angiogenic factor. Human
recombinant FGF2 stimulated colony formation and growth in ECFCs
(Figure 6A and B), and addition of PTX3 to FGF2-treated ECFCs signifi-
cantly inhibited the FGF2 positive effect on endothelial proliferation
(P< 0.001) (Figure 6A and B). We also examined the role of PTX3 in
FGF2-induced angiogenesis using the in vitro 3D Matrigel tubulogenesis
assay. ECFCs labelled green with calcein were cultured in Matrigel in the
presence or absence of FGF2 and PTX3 (Figure 6C). After 48 h, ECFCs
formed a vascular tube network (Figure 6C) and following FGF2 addition
there was a significant enhancement of ECFC tubulogenesis (P< 0.01)
(Figure 6D). When PTX3 was added to this culture system, FGF2 promo-
tion of tube formation was inhibited (P< 0.001) and led to a further sig-
nificant decrease in ECFC tube formation below control levels (Figure 6C
and D). To gain further insight into this PTX3/FGF2 interaction, we used
TNF-stimulated gene 6 protein (TSG6), a ligand for PTX3. Both TSG6
and FGF2 bind to PTX3 with similar affinities. Interestingly, when TSG6
was added to medium in the presence of PTX3 and FGF2, it significantly
reversed the inhibitory effect of PTX3, and restored ECFC tubule forma-
tion to control levels (P< 0.01) (Figure 6C and D). These data
Figure 4 PTX3 mediates HD-CACs anti-angiogenic effects on
MECs. (A) Representative image for 3D Matrigel tubulogenesis model
showing LD CACs in red and MECs in green. (B) Representative image
showing HD CACs in red inhibited MECs tubule formation. (C and D)
PTX3 antibodies targeting the C-terminus (Cterm) and the N-terminus
(Nterm) were added to the co-culture system. Scale bars 300lm. (E)
Quantification of MEC tube area after normalizing to MEC control (red
dashed line at 100%) (Data visualized as stripcharts n¼ 3–6; one-way
ANOVA; ***P< 0.001; ns, not significant).
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demonstrate that PTX3 exerts an anti-angiogenic effect on endothelial
cells by targeting FGF2 signalling.
3.8 Inflammatory cytokines elevated in
HD-CACþMEC co-cultures trigger PTX3
upregulation in endothelial cells
To elucidate the molecular mechanisms driving PTX3 upregulation
and release in our HD-CACþMEC experimental model, we exam-
ined the inflammatory cytokine profiles in CACs at different cellular
densities. RT-qPCR analysis of RNA harvested from CACþMEC co-
cultures revealed a significant increase in expression of inflammatory
cytokines IL1b (Figure 7A) and TNFa (Figure 7B) in HD-CACþMEC
co-culture. Notably, MEC cultures under basal conditions showed no
detectable expression of IL1b and TNFa (Figure 7A and B). We then
examined whether stimulation of endothelial cells with IL1b and
TNFa would increase PTX3 expression. ECFCs were treated with 20
ng/mL IL1b or 40 ng/mL TNFa, and protein was harvested after 5 h
exposure. LPS (500 ng/mL) was used as a classical pro-inflammatory
positive control stimulant. It was observed that ECFCs stimulated
with inflammatory cytokines IL1b, TNFa, and LPS expressed signifi-
cantly higher levels of PTX3 protein when compared to non-
stimulated cells (Figure 7C). PTX3 upregulation as a response of CAC-
exposure to IL1b was consistent among three different biological rep-
licates (see Supplementary material online, Figure S8). According to
our data, we propose a mechanism whereby HD of CACs causes an
increase in the expression of inflammatory cytokines IL1b and TNFa
which induces endothelial expression and release of PTX3 that ulti-
mately acts in an autocrine manner by inhibiting the FGF2 pathway
and impairing endothelial cell function (Figure 7D).
Figure 5 PTX3 produced by endothelial cells in response to HD-CACs acts in an autocrine anti-angiogenic manner. (A) PTX3 expression analysis using
qRT-PCR and bovine or human-specific primers, visualized in a heatmap for three biological replicates. (B) Protein expression analysis in human cell lysates
from CACs and ECFCs for four biological replicates. (C) RT-qPCR to evaluate PTX3-siRNA knockdown efficiency (n¼ 9, one-way ANOVA, ***P< 0.001).
(D) Western blot to assess level of PTX3-siRNA knockdown in ECFCs. (E) Representative images of in vitro 3D Matrigel-based tube formation assay showing
CACs in red and ECFCs in green. Scale bars 300lm (F) Quantification and statistical analysis of ECFC tube areas (n¼ 9, one-way ANOVA, data visualized
as a stripchart, ***P< 0.001 vs. control siRNA-ECFCs, ###P< 0.001 vs. control siRNA-ECFCsþHD-CACs).
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..4. Discussion
The major finding of this study was the consistent switch in CACs angio-
genic potential from being facilitators to inhibitors at different cellular
densities. This is of critical clinical relevance when considering CACs or
comparable cell-types for use in cellular therapies. Although previous
work from our group and others has demonstrated CACs exert pro-
angiogenic effects through the secretion of proangiogenic growth factors
and cytokines, the current investigation is the first to highlight that a HD
of CACs significantly inhibits vascular repair. Although dose-escalation
methods are essential components of clinical trials to ensure safety, it is
evident that marked variability exists between studies. In the case of
ischaemic heart disease, numbers of CD34þ/MNCs administered via
intracoronary infusion varies from 4.3  106 cells per patient16 to num-
bers as high as 3.46 1.2  109 per patient.17 This 103-fold difference
underscores the need to understand the biology associated with changes
in cellular densities used for cell therapies.
Since CACs exert their effects through paracrine mechanisms, it is
assumed that a larger number of cells will be associated with enhanced
therapeutic benefit. Our data strongly rebut this idea and demonstrate
that high-cellular densities of CACs trigger anti-angiogenic responses. A
recent cell therapy clinical trial testing cells with considerable similarity
to CACs for pulmonary arterial hypertension used escalating doses from
7  106 to 50  106 cells. Although this cell therapy was reported as
well-tolerated, there was one serious adverse event which resulted in
the death of a patient treated with 23  106 cells and there was a sug-
gested ‘possible’ link to cell treatment.6 This underscores the importance
and clinical relevance of our research data indicating that CACs pheno-
type and functionality is greatly impacted by their cellular density. A limi-
tation in the mouse OIR model was the maximum feasible cell therapy
Figure 6 PTX3 impairs FGF2-mediated endothelial cell function. (A) Representative images from clonogenic assay. ECFC colonies were stained with crys-
tal violet. Scale bars 250lm. (B) Quantification and statistical analysis of FGF2 and PTX3 effects on ECFC clonogenic potential quantified as the percentage
(%) of total surface area covered by crystal violet staining (n¼ 9, one-way ANOVA, data visualized as a stripchart, ***P< 0.001 vs. control, ###P< 0.001 vs.
FGF). (C) Representative images for 3D Matrigel in vitro model showing tubule formation by ECFCs in green. FGF2 (5 ng/mL), human recombinant PTX3
(500 ng/mL) and TSG6 (1 mg/mL). Scale bars 200lm. (D) Quantification of tube areas (n¼ 8–10, one-way ANOVA, data visualized as a stripchart,
**P< 0.01 vs. control, ###P< 0.001 vs. FGF, $$P< 0.01 vs. FGFþ PTX3).
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..dose of 1 mL containing at most 100 000 cells which did not allow the
testing of HDs used in the murine Matrigel plug angiogenesis assay and
the in vitro experiments. As an alternative approach, the protein pro-
duced by HD CACs, PTX3, was delivered intravitreally and shown to
impair vascular repair in the OIR model.
Isolation of CACs by culturing MNCs in endothelial growth
medium for1 week clearly drives the cell phenotype into a highly
enriched myeloid cell population with M2 macrophage characteristics.
Our data support earlier observations indicating that CACs offer a
more homogenous cell choice than the use of unselected MNCs for
clinical applications.18 Indeed, trials testing the clinical potential of
CAC-like cells such as TOPCARE AMI,7 the autologous ‘EPC’ trial for
AMI and IPAH,19 and PHACeT6 have already shown feasibility, safety
and some beneficial outcomes. Safety concerns have been raised with
the use of unfractionated BM cells because it was reported that they
induced significant intramyocardial calcification.20 Furthermore,
results from some recent clinical trials testing various BM populations
have been in disagreement with earlier positive results and showed
no therapeutic benefit.21 This discrepancy indicates that there is a
need for better characterized and more homogeneous cell
populations.
Identification of PTX3 as the key soluble factor driving angiogenic
inhibition in the HD-CACs is in agreement with previous reports dem-
onstrating that PTX3 acts as an antagonist to FGF signalling by binding
with high affinity to FGF2 and preventing its binding to the tyrosine kin-
ase receptors FGFR1 and FGFR2.22 The blocking of FGF2 signalling by
PTX3 results in inhibition of endothelial cell proliferation and in vivo vas-
cularization in a murine Matrigel subcutaneous implant assay and a chick
embryo model.23 In addition, PTX3 overexpression has also been shown
to inhibit FGF8-induced neovascularization.24
It is the N-terminus of PTX3 which has previously been shown to
bind specifically and with high affinity to FGF2 and FGF8b but not FGF1
or FGF4.14,15 Our data support this because blocking specifically the N-
terminus of PTX3 abrogates the anti-angiogenic effects of HD-
CACþMECs. We further demonstrate that the anti-angiogenic effects
of PTX3 are mediated through the N-terminus of PTX3 (FGF binding
site) by the use of TSG6, a protein that competes for PTX3 binding with
FGF2. TSG6 reversed the inhibitory effect of PTX3 on FGF2-related
endothelial function.
Another key finding was that, rather than CACs, endothelial cells
were the major source of PTX3 in HD-CACþMEC co-cultures. This
was not unexpected because PTX3 was first identified over two decades
Figure 7 CACs at high-cellular density induce upregulation of IL1b and TNFa which increase PTX3 expression in endothelial cells. (A) Evaluation of IL1b
expression by qRT-PCR in co-cultures. ND, not detectable (n¼ 6, one way-ANOVA). (B) TNFa expression assessed by qRT-PCR. ND, not detectable
(n¼ 3, one-way ANOVA). Data expressed as mean6 SEM. ***P< 0.001 vs. LD-CACsþMECs, ###P< 0.001 vs. MD-CACsþMECs, **P< 0.01 vs. LD-
CACsþMECs, and #P< 0.05 vs. MD-CACsþMECs. (C) Western blot for PTX3 expression in ECFCs treated for 5 h with 20 ng/mL IL1b, or 40 ng/mL
TNFa, or 500 ng/mL LPS. (D) Schematic diagram for proposed mechanistic model: HD-CACs upregulate expression of inflammatory cytokines IL1b and
TNFa, which induces endothelial expression and release of PTX3 that ultimately impairs FGF2-induced angiogenesis.
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ago as an IL1b-inducible gene in human umbilical vein endothelial cells
(HUVECs).25 Since then, PTX3 has been shown to be expressed in vari-
ous endothelial beds upon exposure to inflammatory stimuli such as
IL1b and TNFa. A link between vascular inflammation and PTX3 expres-
sion has been shown in diseases such as atherosclerosis26 and small cell
vasculitis.27 We are uncertain of the specific role for basal levels of PTX3
in ECFCs, although it is recognized that PTX3 is expressed in healthy
individuals at low levels (2 ng/mL) but its serum levels increased up to
100-fold following myocardial infarction. Therefore, PTX3 has been sug-
gested as an early diagnosis and prognosis biomarker in cardiovascular
disease.28,29
The species differences between CACs (human origin) and MECs
(bovine origin) in our experimental model have allowed us to unequivo-
cally determine the cellular source of PTX3. Bovine PTX3 has 81.9%
sequence homology with human PTX3 and previously it was demon-
strated that human PTX3 has functional effects on bovine aortic endo-
thelial GM 7373 cells14 and in the murine vasculature.30 In agreement
with this, our data showed that recombinant human PTX3 inhibited
endothelial tube formation in both bovine and human cells.
In conclusion, our findings reveal that CACs represent a highly
enriched population of cells and thus constitute a more-defined popula-
tion for cell therapy than BM-MNCs. However, considering the myeloid
nature of CACs, we highlight the need for optimal cell numbers of CACs
to be carefully considered in clinical trials because we demonstrated that
the use of high cell numbers has a negative impact on reparative angio-
genesis. We propose a mechanistic model where CACs (and similar
myeloid cells) at high-cellular densities produce a pro-inflammatory
secretome which inflames endothelium that releases PTX3 with conse-
quent autocrine inhibition of FGF2-induced vascular repair.
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Supplementary material is available at Cardiovascular Research online.
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